Mersana Therapeutics Inc (NASDAQ:MRSN) Expected to Announce Earnings of -$0.37 Per Share

Wall Street analysts expect that Mersana Therapeutics Inc (NASDAQ:MRSN) will announce earnings of ($0.37) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Mersana Therapeutics’ earnings. The highest EPS estimate is ($0.36) and the lowest is ($0.39). Mersana Therapeutics posted earnings of ($0.75) per share in the same quarter last year, which suggests a positive year over year growth rate of 50.7%. The business is scheduled to announce its next earnings report on Tuesday, November 12th.

According to Zacks, analysts expect that Mersana Therapeutics will report full-year earnings of ($0.62) per share for the current fiscal year, with EPS estimates ranging from ($0.78) to ($0.38). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.44) per share, with EPS estimates ranging from ($1.84) to ($1.20). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Mersana Therapeutics.

Mersana Therapeutics (NASDAQ:MRSN) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.36) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.38) by $0.02. The company had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $1.08 million. Mersana Therapeutics had a negative net margin of 77.78% and a negative return on equity of 51.13%.

A number of research analysts have recently issued reports on MRSN shares. Zacks Investment Research cut shares of Mersana Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. ValuEngine upgraded shares of Mersana Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Two equities research analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $10.17.

NASDAQ:MRSN traded down $0.01 during trading hours on Thursday, reaching $1.65. The company had a trading volume of 108,190 shares, compared to its average volume of 413,895. The business’s 50-day simple moving average is $1.82 and its two-hundred day simple moving average is $3.61. Mersana Therapeutics has a twelve month low of $1.40 and a twelve month high of $8.71. The company has a current ratio of 5.50, a quick ratio of 5.50 and a debt-to-equity ratio of 0.06.

Several hedge funds and other institutional investors have recently modified their holdings of MRSN. Marshall Wace LLP bought a new position in Mersana Therapeutics during the 1st quarter valued at $141,000. Sphera Funds Management LTD. purchased a new stake in shares of Mersana Therapeutics during the first quarter worth $1,052,000. Acadian Asset Management LLC purchased a new stake in shares of Mersana Therapeutics during the second quarter worth $204,000. Russell Investments Group Ltd. increased its position in Mersana Therapeutics by 41.8% during the second quarter. Russell Investments Group Ltd. now owns 13,900 shares of the company’s stock worth $56,000 after buying an additional 4,100 shares during the last quarter. Finally, Panagora Asset Management Inc. acquired a new position in Mersana Therapeutics during the second quarter worth $397,000. Hedge funds and other institutional investors own 83.57% of the company’s stock.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.

Further Reading: What is the Fibonacci sequence?

Get a free copy of the Zacks research report on Mersana Therapeutics (MRSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.